Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "GenMark Diagnostics, Inc." (GNMK) Report Updated: Jul 22, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"GenMark Diagnostics, Inc." (GNMK)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Health Care Equipment & Supplies

Stock Analysis

Rating: Monthly View

July August September October November December January February March April May June

Rating: Weekly View

This Week: B down upgrade
Last Week: C same downgrade
Two Weeks Ago: B up upgrade
service keys

"GenMark Diagnostics, Inc."© quotemedia

Company Profile

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. The company offers eight diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test, Respiratory Viral Panel, hepatitis C virus, genotyping tests, a 3A4/3A5 genotyping test, and a 2C19 genotyping test. It also provides ePlex system, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using the ePlex system to place the patient sample into the test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.